GlassScriptPhysician profile
Watta Martha Grant
NPI 1780257915
$2,631.50
in general payments reported to CMS, 2019-2025
16 companies · $834 in 2025
The $834 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $394 · 2023: $781 · 2024: $622 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.72 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $576.35 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $192.58 | 2022-2023 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $172.15 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $145.05 | 2022-2023 | Rexulti, Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $131.59 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $79.18 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $78.33 | 2023-2024 | Rexulti |
| Alkermes, INC. | $76.35 | 2023-2024 | Aristada, Lybalvi |
| Gilead Sciences, INC. | $58.55 | 2025 | Epclusa |
| Merck Sharp & Dohme LLC | $31.50 | 2024-2025 | Pifeltro, Capvaxive |
| Eisai INC. | $20.82 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.46 | 2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $19.30 | 2025 | Qelbree |
| Viatris Specialty LLC | $17.13 | 2025 | Yupelri |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.44 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Watta Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.